The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL
Martin Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase Ib study of venetoclax (ABT-199) and obinutuzumab, an anti-CD20 antibody, in relapsed/refractory or previously untreated chronic lymphocytic leukaemia (CLL). The preliminary data show patients achieving minimum residual disease (MRD) states with no toxicity.
